Executive Director's Letters
Welcome To The Blog!
I will never forget my experience with LCH, as I am sure is true for so many histiocytosis patients, families, and friends. I can still remember what it felt like to hear a diagnosis of a rare disease, the visits to the hospital, the pain, the uncertainty, the heroes on my medical team – it is all vivid as though it were only a week ago. One of the most important pieces of recovery for me, was the opportunity to connect with other families and patients; to hear their stories and learn from their experience. The world of rare disease can feel lonely, and it is often hard to talk about what we have seen, felt, and been through. Even if we meet someone who has suffered from a rare or debilitating condition, their journey may have been very different from our own. Years ago, we did not have the technology we do today to email one another or to connect on social media. We connected through a PenPal club, finding comfort in the words of others, pressed into the lined paper or edges of notebooks and sent via mail to the eager eyes of a fellow Histio Warrior or family member. I still have so many letters from the PenPal club. They are tucked away in a special box in my house and are a memory I treasure. I admit, I revisit those words and stories often.
Now, everything has become digital. And the benefit of that is the far-reaching edges of the world that we can all now touch. So, this blog, along with the Beyond the Diagnosis Podcast, our regional/local meetings, and any community engagements we can facilitate, are our way of connecting with you. I invite you to come along with the Association Team as we share our work, share stories of warriors and families, and bring you deeper into the impact you all have on us. I encourage you to comment, share, and to bring new ideas forward to me; know that while these are just my thoughts down on paper, they are meant for each one of you, to be a source of connection and to talk about the topics most important to you.
I look forward to these posts and look forward to hearing what you would like to hear!
You may have heard the exciting news, that on November 1st, 2022, Memorial Sloan Kettering Cancer Center (MSK) announced that the U.S. Food and Drug Administration (FDA) approved the oral MEK inhibitor drug cobimetinib (Cotellic®) for the treatment of adult patients diagnosed with histiocytic neoplasms (HN).Read More
Collaboration noun. – The action of working with someone to produce or create something. A common part of our daily lives, and a critical part of advancing research for histiocytosis…Read More
It’s always a great feeling when we get to bring good news to this blog. There are many challenges that those with histiocytic disorders may face, but there are also…Read More
This is part 2 of our series recapping the events of the 38th Annual Histiocyte Society meeting. Click here for part 1. Every 3 years there is a passing of…Read More
On September 17th, the Board of the Histiocyte Society gathered in Karolinska Institute in Stockholm, Sweden to kick off the 38th Annual Meeting of the Histiocyte Society, which continued on for the next three days. Being in my mid-thirties, it is inspiring and humbling that for my entire life, there has been an international effort toward advancing knowledge about histiocytic disorders and improving outcomes for patients through the planning, development, sponsorship and oversight of clinical research.Read More